Scotiabank analyst Louise Chen has reaffirmed her Buy rating for Teva Pharmaceutical Industries (TEVA), setting a price target of $47.00. The recommendation comes as Teva’s shares closed at ILA12,630.00 on the previous trading day. Chen, who covers the Healthcare sector and tracks companies like Johnson & Johnson, Merck & Company, and Amgen, has a track record of an 8.1% average return and a 54.23% success rate on recommended stocks, according to TipRanks.
The broader market sentiment leans heavily in favor of Teva, with analysts collectively assigning a Strong Buy consensus rating. The average price target across analysts stands at $47.24, though this implies a significant -99.63% downside from current levels. Leader Capital Markets also maintained a Buy rating, with a notably higher price target of ILA15,350.00.
Teva’s latest earnings report for the quarter ending June 30 revealed a quarterly revenue of ILA4.14 billion and a GAAP net loss of ILA576 million. This contrasts with the same period last year, when the company reported slightly higher revenue of ILA4.18 billion and a net profit of ILA282 million.